Status: Recruiting
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Panagiotis Konstantinopoulos, MD, PhDUpdated: Jan 7, 2026Locations: 2
Eligibility criteria
Participants must have endometrial cancer that is ARID1A-mutated [loss of functi... [+15]
Participants who have had chemotherapy, immunotherapy, other investigational the... [+24]